Rethinking 30-day readmission in patients with hip fracture: the role of early mobilisation
Published
May 24, 2026
Paper ID
PAP-000273
Status
Published
DOI
10.65712/tmj.test000531
Advance Services
Abstract
Background: Earlier studies of early mobilisation were small or single-centre. Methods: We conducted a pilot feasibility study across 2 centres between 2014 and 2025. Results: Effects were consistent across prespecified subgroups. 1593 participants were included (median age 50 years). Conclusion: Future work should test early mobilisation in a pragmatic multicentre trial.
Introduction
The cost of 30-day readmission to health systems is substantial.
The cost of 30-day readmission to health systems is substantial. Guidelines make only a weak recommendation on early mobilisation.
Earlier studies of early mobilisation were small or single-centre. Guidelines make only a weak recommendation on early mobilisation.
Discussion
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. These findings suggest that early mobilisation is associated with better 30-day readmission in patients with hip fracture.
These findings suggest that early mobilisation is associated with better 30-day readmission in patients with hip fracture.
These findings suggest that early mobilisation is associated with better 30-day readmission in patients with hip fracture. Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
Conclusions
Early mobilisation merits wider use for patients with hip fracture to improve 30-day readmission.
References
1. Silva E, Osei J, et al. Early enteral nutrition and 30-day readmission. Pediatrics. 2023;82(1):327-1062.
2. Larsen U, Schmidt R, et al. High-flow nasal oxygen and medication adherence. Diabetes Care. 2022;105(8):885-1466.
3. Mueller C, Mensah F, et al. High-flow nasal oxygen and length of stay. BMJ. 2008;308(5):789-1660.
4. Zhang S, Yilmaz C, et al. Pharmacist-led medication review and health-related quality of life. BMJ. 2012;258(11):175-1485.
5. Tanaka L, Herrera C, et al. SGLT2 inhibitors and health-related quality of life. Lancet. 2011;135(5):505-1379.
6. Ibrahim T, Andersen A, et al. An antibiotic stewardship programme and ventilator-free days. Ann Intern Med. 2014;53(4):135-1017.
Appendices
Supplementary tables are available on request.
Materials and Methods
We conducted a pilot feasibility study across 5 centres between 2020 and 2025. We conducted a pilot feasibility study across 13 centres between 2015 and 2023. Analyses were adjusted for age, sex and baseline severity.
Missing data were handled with multiple imputation. The primary outcome was 30-day readmission, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.
We conducted a pilot feasibility study across 11 centres between 2018 and 2022. Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 3 centres between 2018 and 2025. Missing data were handled with multiple imputation.
Results
The adjusted odds ratio was 0.53 (95% CI 0.49 to 0.73). Serious adverse events were rare and similar between groups.
Serious adverse events were rare and similar between groups. 30-day readmission occurred in 14% of the intervention group versus 27% of controls. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.50 (95% CI 0.22 to 0.75).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Age < 65 | 297 | 20 | 28.2 | 0.95 |
| Age ≥ 65 | 587 | 57 | 15.0 | 0.63 |
| Male | 739 | 49 | 14.7 | 0.40 |
| Intervention | 371 | 85 | 38.9 | 0.48 |
| Age < 65 | 551 | 13 | 14.7 | 0.68 |
| Age < 65 | 205 | 61 | 8.8 | 0.96 |
| Age < 65 | 455 | 73 | 13.9 | 0.91 |
Values are n (%) unless stated otherwise.

Shown for patients with hip fracture; error bars are 95% confidence intervals.

Shown for patients with hip fracture; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. 2433 participants were included (median age 69 years).
Serious adverse events were rare and similar between groups. 1657 participants were included (median age 62 years). The adjusted odds ratio was 0.46 (95% CI 0.22 to 0.64). 1312 participants were included (median age 59 years).